Literature DB >> 1968415

Discrepancies in lipolytic activities induced by beta-adrenoceptor agonists in human and rat adipocytes.

C Hollenga1, M Haas, J T Deinum, J Zaagsma.   

Abstract

A number of catecholamine and non-catecholamine beta-adrenoceptor agonists, including the lipolytically selective compound BRL 37344, were compared for lipolytic activity on human and rat adipocytes. On rat adipocytes, all compounds were full agonists, BRL 37344 being the most potent. On human adipocytes, only the catecholamines were full beta-adrenoceptor agonists. The other compounds were partial agonists, with intrinsic activities declining in the order fenoterol greater than salbutamol greater than clenbuterol greater than BRL 37344. This was the case with FFA- as well as with glycerol-production. Addition of 20 microM phentolamine did not enhance BRL 37344 activity. The isoprenaline- and BRL 37344-induced lipolysis on rat white adipocytes was stereoselectively antagonized by enantiomers of alprenolol, with atypical low potencies and stereoselectivity. It was concluded that (1) human and rat adipocyte beta-adrenoceptors mediating lipolysis are not essentially different, (2) partial agonism in human adipocytes is not explained by enhanced re-esterification and (3) BRL 37344 selectively stimulates rat adipocyte lipolysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968415     DOI: 10.1055/s-2007-1004839

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  14 in total

1.  Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

2.  Functional evidence that alpha 2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells.

Authors:  G Tarkovács; C Blandizzi; E S Vizi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

3.  The beta-adrenoceptors mediating relaxation of rat oesophageal muscularis mucosae are predominantly of the beta 3-, but also of the beta 2-subtype.

Authors:  R E de Boer; F Brouwer; J Zaagsma
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

4.  Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A.

Authors:  C A Williams; M F Shih; P V Taberner
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

5.  Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum.

Authors:  J W Growcott; C Wilson; B Holloway; S Mainwaring
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue.

Authors:  P Barbe; L Millet; J Galitzky; M Lafontan; M Berlan
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

7.  Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor.

Authors:  N Blin; C Nahmias; M F Drumare; A D Strosberg
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

8.  Demonstration of an in vivo functional beta 3-adrenoceptor in man.

Authors:  S Enocksson; M Shimizu; F Lönnqvist; J Nordenström; P Arner
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man.

Authors:  D M Newnham; C G Ingram; A Mackie; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

10.  Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise.

Authors:  E Santti; R Huupponen; J Rouru; V Hänninen; U Pesonen; M Jhanwar-Uniyal; M Koulu
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.